



Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards

October, 2012

Plantation, Florida -- [Goodwin Biotechnology, Inc. \(GBI\)](#) has been named a three-category winner in the 2012 CMO Leadership Awards presented by *Life Science Leader* magazine. GBI was rated in the top 20% for Innovation, Productivity and Regulatory.

“We at GBI are honored to be recognized in three categories of the CMO Leadership Awards, and consider it a testament to the quality of our people and their dedication to our customers,” noted Bansi K. Bhan, Interim CEO at Goodwin Biotechnology, Inc. “Regarding innovation, our scientists take great pride in identifying and implementing solutions to the most complex challenges. We are also proud of the Productivity award because we have established a history of meeting and exceeding our clients’ expectations by consistently delivering on agreed upon objectives. Further, from a regulatory perspective, we focus on both quality and compliance as a single source for biologics development and manufacturing from cell line engineering and proof of concept through to cGMP manufacturing of late-stage clinical trial material.”

Life Science Leader developed the annual CMO Leadership Awards in 2011 to honor top outsourcing industry performers based on leading research to better serve pharmaceutical and biopharmaceutical executives in the CMO vetting process. *Life Science Leader* partnered with the professional marketing research agency, Nice Insight, who created a methodology that combines the surveying of thousands of industry executives with other key analyses, such as review of marketing material, to facilitate better overall outsourcing collaborations.

Nice Insight is moving into its third year of conducting primary research on the outsourcing practices of pharmaceutical and biotechnology executives. For the 2012 CMO Leadership Awards survey, the sample size was over 10,000 executives who provided their perceptions on 170 contract manufacturing organizations (CMOs). The companies that service the drug development cycle were rated on six key drivers in outsourcing – Quality, Reliability,

Productivity, Regulatory, Affordability, and Innovation. Leadership Award winners scored in the top 20% of all CMOs in each of the previously mentioned categories.

“At *Life Science Leader*, we think that data-driven awards are more objective and valuable than recognizing companies as a result of a nomination and voting process,” shared Rob Wright, Editor in Chief, *Life Science Leader*. “The core of the research is focused on awareness, or how well a CMO and its service offering are known within the outsourcing industry, and customer perceptions, or how the business is regarded by the potential and current buyers of outsourced services. The winners should be proud of these awards because they were determined by the perceptions of their target audiences.”

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a world-class CMO that offers fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, proof of concept, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary [conjugation](#) technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely and cGMP compliant manner to enhanced patients' lives. With 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

For more information, please contact:

Goodwin Biotechnology:

Dave Cunningham

Director of Marketing & Administration

(954) 327-9639

DCunningham@goodwinbio.com